Natco Pharma, one of the few Indian companies to venture into new drug discovery research, jumped on Monday after the US Supreme Court chief justice Roberts denied Teva's application for an injunction seeking to prevent launch of a generic version of Copaxone pending the Supreme Court's decision on Teva's appeal.

"This is the second time that the chief justice has denied Teva's request for such an injunction," it said.

Shares of the company are trading at Rs 769.50, up Rs 53.85, or 7.52% at the Bombay Stock Exchange (BSE) on Monday at 12:07 p.m.

The scrip has touched an intra-day high of Rs 808.15 and low of Rs 758.30. The total volume of shares traded at the BSE is 79,611.

In the earlier session, the shares climbed 1.34%, or Rs 9.44, at Rs 715.65. Currently, the stock is trading down 12.26% from its 52-week high of Rs 877 and above 97.31% over the 52-week low of Rs 390.